Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 13;31(164):210264.
doi: 10.1183/16000617.0264-2021. Print 2022 Jun 30.

COVID-19 and tuberculosis: the double whammy of respiratory pathogens

Affiliations
Review

COVID-19 and tuberculosis: the double whammy of respiratory pathogens

Mohd Shariq et al. Eur Respir Rev. .

Abstract

Prior to coronavirus disease 2019 (COVID-19), tuberculosis (TB) was the worst killer among infectious diseases. The union of these two obnoxious respiratory diseases can be devastating, with severe public health implications. The COVID-19 pandemic has affected all TB-elimination programmes due to the severe burden on healthcare systems and the diversion of funds and attention towards controlling the pandemic. The emerging data show that the COVID-19 pandemic caused a marked decrease in case notifications and bacille Calmette-Guérin immunisations, ultimately promoting disease transmission and increasing the susceptible population. The similarity between the clinical characteristics of TB and COVID-19 adds to the public health complications, with evidence of immune dysregulation in both cases leading to severe consequences. Clinical evidence suggests that severe acute respiratory syndrome coronavirus 2 infection predisposes patients to TB infection or may lead to reactivation of latent disease. Similarly, underlying TB disease can worsen COVID-19. Treatment options are limited in COVID-19; therefore, using immunosuppressive and immunomodulatory regimens that can modulate the concomitant bacterial infection and interaction with anti-TB drugs requires caution. Thus, considering the synergistic impact of these two respiratory diseases, it is crucial to manage both diseases to combat the syndemic of TB and COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Shariq has nothing to disclose. Conflict of interest: J.A. Sheikh has nothing to disclose. Conflict of interest: N. Quadir has nothing to disclose. Conflict of interest: N. Sharma has nothing to disclose. Conflict of interest: S.E. Hasnain has nothing to disclose. Conflict of interest: N.Z. Ehtesham has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
a) Data from the Nikshay tuberculosis (TB) notification system reported in India from 2017 to 2021. Cases notified are average cases notified per month calculated based on annual notified cases. Source: Nikshay, Central TB Division, National TB Elimination Programme. b) The number of coronavirus disease 2019 (COVID-19)-infected patients reported in India from January 2020 to October 2021. Source: worldometers.info. c) Number of TB notified cases monthly in India from January 2020 to October 2021. Source: Nikshay, Central TB Division, National TB Elimination Programme. d) Global map showing countries that reported different TB/COVID-19 coinfection numbers. e) Routine bacillus Calmette–Guérin (BCG) immunisation data in neonates from India's National Health Mission's Health Management Information System from January 2020 to March 2021. Source: National Health Mission's Health Management Information System.

References

    1. World Health Organization . Global Tuberculosis Report 2021. Geneva, WHO, 2021.
    1. Chakaya J, Khan M, Ntoumi F, et al. . Global Tuberculosis Report 2020 – Reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis 2021; 113: S7–S12. doi:10.1016/j.ijid.2021.02.107. - DOI - PMC - PubMed
    1. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 2016; 13: e1002152. doi:10.1371/journal.pmed.1002152 - DOI - PMC - PubMed
    1. Khayat M, Fan H, Vali Y. COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report. Respir Med Case Rep 2021; 32: 101344. doi:10.1016/j.rmcr.2021.101344 - DOI - PMC - PubMed
    1. Sironi M, Hasnain SE, Rosenthal B, et al. . SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. Infect Genet Evol 2020; 84: 104384. doi:10.1016/j.meegid.2020.104384 - DOI - PMC - PubMed

Substances